Vol. 4, Issue 1 (2015)

Author(s):
Iryna Savelikhina, Mykola Ostrovskyy (JR), Olena Deltsova, Sergiy Gerashchenko, Mykola Ostrovskyy.

Abstract:
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible chronic airflow limitation that usually leads to a progressive decline in lung function over time. The development of COPD is associated with both chronic airway and systemic inflammation. Roflumilast – a phosphodiesterase-4 (PDE4) inhibitor –represents a new class of drug in the management of COPD. Through selective inhibition of the PDE4 enzyme, roflumilast prevents the breakdown of cyclic AMP, which plays an important role in regulating inflammatory cell activity. Remodeling of respiratory tracts is a pathologic process observed at chronic inflammatory and obstructive diseases of respiratory tracts, and it is prescribed on the background of a COPD maintenance treatment. For 9 people with severe COPD before treatment and after 30 and 180 days treatment with roflumilast were performed biopsies of the mucous membrane of the bronchi. Verification of the diagnosis and its formulation confirmed with the orders of Ministry of Health of Ukraine № 128 from 19.03.2007. "On approval of clinical protocols of medical care in the specialty pulmonology".